Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4951 - Loss of HLA class I expression and T-cell infiltration or PD-L1 expression are associated with different response patterns to pembrolizumab in melanoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Immunotherapy;  Pathology/Molecular Biology

Tumour Site

Melanoma

Presenters

Alexia Degraeuwe

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

A. Degraeuwe1, N. van Baren2, F. Cornelis3, P. van Eeckhout4, J. Baurain5

Author affiliations

  • 1 Medical Oncology, Université catholique Louvain, 1200 - Bruxelles/BE
  • 2 Institut De Duve, Université catholique Louvain, 1200 - Bruxelles/BE
  • 3 Medical Oncology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 4 Anatomopathologie, Cliniques Universitaires St. Luc, 1200 - Bruxelles/BE
  • 5 King Albert 2 Cancer Institute, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
More

Resources

Abstract 4951

Background

PD-1 blockade monoclonal antibodies, nivolumab and pembrolizumab, increase quality of life and overall survival of metastatic melanoma and are today’s first-line treatment of metastatic melanoma. Nevertheless, only 40% of the patients will respond to anti-PD-1 monotherapy. In the era of personalized medicine, an important stake is to identify the patients who will benefit from these treatments, which are also responsible for scare but serious side effects. We have tested several biomarkers to discriminate between responders and non-responders.

Methods

We have retrospectively analysed 18 patients treated by pembrolizumab for metastatic melanoma. Immunohistochemical staining was performed on pre-treatment metastatic tissue for antigens such as MELANA, TYR, GP100, PD-L1, CD3, CD8, IDO1, HLA class I heavy chain and β2-microglobulin. Two reviewers assessed the staining independently. For PD-L1 testing, the MEL-score was used. For T-cell infiltration, we have quoted the presence of CD3 CD8 T cell and their location.

Results

We found that only PD-L1 expression and the presence of T-cell infiltration were associated with a better response to pembrolizumab: PD-L1 expression (p = 0,043), T-cell infiltration (p = 0,025) and T-cell location at the periphery of the tumoral nodules (p = 0,025). PD-L1 expression and the presence of T lymphocytes were also associated with a longer survival. The median overall survival was 31,5 months for the T-cell rich metastasis and PD-L1 high expression versus 4 months for non T-cell infiltrated tumours and 7 months for PD-L1 negative tumours. Furthermore, 50% of the metastases showed reduced or absent HLA class I expression by the tumour cells. The role of tumoral HLA loss in response and resistance to PD-1 blockade has still to be defined.

Conclusions

Although significant correlations were observed between some biomarkers and the response to anti-PD-1 therapy as described in larger studies, no predictive biomarker has currently been identified in our small series. Recent and future technical progresses will enable new studies aiming to find reliable biomarkers and to clarify the complex mechanisms of response and resistance to immune checkpoint inhibitors.

Clinical trial identification

Legal entity responsible for the study

Cliniques universitaires Saint-Luc.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.